

IN THE CLAIMS

Please amend the claims as follows:

1-3. (Canceled)

4. (Previously Presented) The method according to claim 26, wherein the antibody is a modified antibody and wherein said modification is selected from amino acid substitution and chemical modification.

5. (Cancelled).

6. (Cancelled).

7. (Previously Presented) The method according to claim 26, wherein the antibody is a monoclonal antibody.

8. (Currently Amended) The method according to claim 26 or 28, wherein the low vasopressin level results from cancer.

9. (Currently Amended) A method of treating at least one symptom selected from the group consisting of polyuria, dehydration, mouth dryness and hyperosmolarity caused by a decrease in vasopressin level in blood comprising administering to a patient at least one humanized anti-parathyroid hormone related protein 1-34 (anti-PTHrP (1-34)) antibody, or binding fragment thereof in an amount sufficient to inhibit a decrease or increase the vasopressin level in the blood of the patient, wherein the at least one humanized anti-parathyroid hormone related protein 1-34 (anti-PTHrP (1-34)) antibody, or binding fragment thereof that, inhibits the binding between PTHrP and a receptor thereof, allowing the antibody to inhibit the binding of PTHrP and its receptor, and increasing vasopressin level in the blood, wherein the antibody, or binding fragment thereof, binds specifically to SEQ ID NO: 75, and wherein the antibody neutralizes bioactivities of parathyroid hormone related protein [[1-34]].

10. (Previously Presented) The method according to claim 9, wherein the decrease in vasopressin level results from cancer.

11-24. (Canceled)

25. (Currently Amended) The method according to claim 26, wherein the antibody fragment is Fab, scFv, F(ab')2 F(ab')2 or Fv.

26. (Currently Amended) A method of maintaining inhibit a decrease or increasing [[low]] vasopressin level in blood comprising administering to a patient at least one humanized anti-parathyroid hormone related protein 1-34 (anti-PTHrP (1-34)) antibody, or binding fragment thereof in an amount sufficient to decrease or increase the vasopressin level in the blood of the patient, wherein the at least one humanized anti-parathyroid hormone related protein 1-34 (anti-PTHrP (1-34)) antibody, or binding fragment thereof that inhibits the binding between PTHrP and a receptor thereof, allowing the antibody to inhibit the binding of PTHrP and its receptor, and maintaining or increasing vasopressin level, wherein the antibody, or binding fragment thereof, binds specifically to SEQ ID NO: 75, and wherein the antibody neutralizes bioactivities of parathyroid hormone related protein [[1-34]].

27-28. (Canceled)